HIV-1 neuroimmunity in the era of antiretroviral therapy

Neurobiology of Disease

Volumn 37, Issue 3, 2010, Pages 542-548

  Kraft Terry, Stephanie D ^a   Stothert, Andrew R ^a   Buch, Shilpa ^a   Gendelman, Howard E ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Adaptive immunity; Adjunctive therapies; Blood brain barrier; Chemokines; Cognitive dysfunction; Hematopoietic stem cells; HIV 1 associated neurocognitive disorders; Innate immunity; Microglia; Neuroinflammation; Proinflammatory cytokines

Indexed keywords

CD163 ANTIGEN; CD34 ANTIGEN; CD68 ANTIGEN; CEP 1347; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDINAVIR; LITHIUM SALT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEMANTINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; PMS 601; RANTES; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; VALPROIC ACID; ZIDOVUDINE;

ADAPTIVE IMMUNITY; BLOOD BRAIN BARRIER; CD8+ T LYMPHOCYTE; CELL MATURATION; COGNITIVE DEFECT; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; LIFE CYCLE; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VIROGENESIS; VIRUS TRANSMISSION;

AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; ENCEPHALITIS; HIV-1; HUMANS; MONOCYTES; NEUROGLIA; NEUROIMMUNOMODULATION;

EID: 75949100300     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.12.015     Document Type: Review

References (126)

1. Achmat Z., and Simcock J. Combining prevention, treatment and care: lessons from South Africa. Aids 21 Suppl. 4 (2007) S11-S20
2. Alexaki A., et al. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 6 (2008) 388-400
3. Aline F., et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 27 (2009) 5284-5291
4. Ances B.M., and Ellis R.J. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 27 1 (2007) 86-92
5. Anderson E.R., et al. Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J. Neurosci. 24 (2004) 7194-7198
6. Andras I.E., et al. Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J. Cereb. Blood Flow. Metab. 25 (2005) 1159-1170
7. Ansari A.W., et al. Dichotomous effects of C-C chemokines in HIV-1 pathogenesis. Immunol. Lett. 110 (2007) 1-5
8. Antinori A., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69 (2007) 1789-1799
9. Aracena-Genao B., et al. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico. AIDS 22 Suppl. 1 (2008) S141-S148
10. Asensio V.C., and Campbell I.L. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. 22 (1999) 504-512
11. Asensio V.C., et al. Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J. Virol. 75 (2001) 7067-7077
12. Avison M.J., et al. Neuroimaging correlates of HIV-associated BBB compromise. J. Neuroimmunol. 157 (2004) 140-146
13. Baert L., et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72 (2009) 502-508
14. Bangham C.R. CTL quality and the control of human retroviral infections. Eur. J. Immunol. 39 (2009) 1700-1712
15. Banks W.A., et al. Partial saturation and regional variation in the blood-to-brain transport of leptin in normal weight mice. Am. J. Physiol. Endocrinol. Metab. 278 (2000) E1158-1165
16. Banks W.A., et al. Binding, internalization, and membrane incorporation of human immunodeficiency virus-1 at the blood-brain barrier is differentially regulated. Neuroscience 128 (2004) 143-153
17. Battegay M., and Elzi L. Morbidity and mortality in HIV-infected individuals-a shift towards comorbidities. Swiss Med. Wkly. 139 (2009) 564-570
18. Beduneau A., et al. Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS ONE e4343 (2009) 4
19. Bellizzi M.J., et al. Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J. Clin. Invest. 115 (2005) 3185-3192
20. Berry C.C. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomed 3 (2008) 357-365
21. Blankson J.N. Viral reservoirs and HIV-specific immunity. Curr. Opin. HIV AIDS 1 (2006) 147-151
22. Bolin L.M., et al. Primary sensory neurons migrate in response to the chemokine RANTES. J. Neuroimmunol. 81 (1998) 49-57
23. Brabers N.A., and Nottet H.S. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur. J. Clin. Invest. 36 (2006) 447-458
24. Cabral G.A. Drugs of abuse, immune modulation, and AIDS. J. Neuroimmune. Pharmacol. 1 (2006) 280-295
25. Cao W., et al. Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res. Hum. Retroviruses 25 (2009) 183-191
26. Card C.M., et al. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells. J. Infect. Dis. 199 (2009) 1318-1322
27. Christo P.P., et al. Cerebrospinal fluid levels of chemokines in HIV infected patients with and without opportunistic infection of the central nervous system. J. Neurol. Sci. 287 (2009) 79-83
28. Cohen G.M. Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries. Aids 21 Suppl. 4 (2007) S81-87
29. Coleman C.M., and Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6 (2009) 51
30. Conant K., et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3117-3121
31. Crews L., et al. Molecular pathology of neuro-AIDS (CNS-HIV). Int. J. Mol. Sci. 10 (2009) 1045-1063
32. Cysique L.A., and Brew B.J. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol. Rev. 19 (2009) 169-185
33. Cysique L.A., et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73 (2009) 342-348
34. Dallasta L.M., et al. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155 (1999) 1915-1927
35. Deshmane S.L., et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon. Cytokine Res. 29 (2009) 313-326
36. Dhillon N.K., et al. Roles of MCP-1 in development of HIV-dementia. Front. Biosci. 13 (2008) 3913-3918
37. Dou H., et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183 (2009) 661-669
38. Eggert, D., et al., 2010. Neuroprotective activities of CEP-1346 in models of neuroAIDS. Journal of Immunology. 184, 746-756.
39. Eggert D., et al. Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. J. Neuroimmunol. 213 (2009) 47-59
40. + monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178 (2007) 6581-6589
41. Eugenin E.A., and Berman J.W. Gap junctions mediate human immunodeficiency virus-bystander killing in astrocytes. J. Neurosci. 27 (2007) 12844-12850
42. Eugenin E.A., et al. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J. Neurochem. 85 (2003) 1299-1311
43. Everall I., et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J. Neurovirol. (2009) 1-11
44. Everall I.P., et al. The shifting patterns of HIV encephalitis neuropathology. Neurotox. Res. 8 (2005) 51-61
45. Fischer-Smith T., and Rappaport J. Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev. Mol. Med. 7 (2005) 1-26
46. Fischer-Smith T., et al. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J. Neurovirol. 14 (2008) 318-326
47. Fischer-Smith T., et al. CD163/CD16 coexpression by circulating monocytes/macrophages in HIV: potential biomarkers for HIV infection and AIDS progression. AIDS Res. Hum. Retroviruses 24 (2008) 417-421
48. Gendelman H.E., et al. Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 7086-7090
49. Gendelman H.E., et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J. Infect. Dis. 178 (1998) 1000-1007
50. Genis P., et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J. Exp. Med. 176 (1992) 1703-1718
51. Giri M.S., et al. Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J. Immunol. 182 (2009) 4459-4470
52. Gosselin R.D., et al. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones. J. Neurochem. 95 (2005) 1023-1034
53. Govender T., et al. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 15 (2008) 493-501
54. Gray F., et al. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J. Neurovirol 11 Suppl. 3 (2005) 16-22
55. Gruters R.A., et al. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 20 (2002) 2011-2015
56. + T-cells: function and response to HIV infection. Curr. HIV Res. 2 (2004) 23-37
57. Haase A.T. Pathogenesis of lentivirus infections. Nature 322 (1986) 130-136
58. Hasegawa A., et al. The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood (2009)
59. Hesselgesser J., et al. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J. Immunol. 160 (1998) 877-883
60. + T cells in the pathobiology of neurodegenerative disorders. J. Neuroimmunol. 211 (2009) 3-15
61. Hull M.W., et al. Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest 134 (2008) 1287-1298
62. Ivey N.S., et al. Acquired immunodeficiency syndrome and the blood-brain barrier. J. Neurovirol. 15 (2009) 111-122
63. + monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection. J. Infect. Dis. 196 (2007) 38-42
64. Jones M., et al. Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement. J. Neuropathol. Exp. Neurol. 57 (1998) 563-570
65. Kanmogne G.D., et al. HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia. J. Neuropathol. Exp. Neurol. 61 (2002) 992-1000
66. Kanmogne G.D., et al. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. J. Neuropathol. Exp. Neurol. 64 (2005) 498-505
67. Kiertiburanakul S., and Sungkanuparph S. Emerging of HIV drug resistance: epidemiology, diagnosis, treatment and prevention. Curr. HIV Res. 7 (2009) 273-278
68. Kim W.K., et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am. J. Pathol. 168 (2006) 822-834
69. + T cells in vitro. AIDS Res. Hum. Retroviruses 23 (2007) 438-450
70. Kolb S.A., et al. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J. Neuroimmunol. 93 (1999) 172-181
71. Kramer-Hammerle S., et al. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 111 (2005) 194-213
72. Kraft-Terry S.D., et al. A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 65 (2009) 133-145
73. Krusi A., et al. Social and structural determinants of HAART access and adherence among injection drug users. Int. J. Drug Policy (2009)
74. Lambotte O., et al. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol. 13 (2003) 95-103
75. Langford T.D., et al. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain. Pathol. 13 (2003) 195-210
76. Letendre S., et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65 (2008) 65-70
77. + regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J. Immunol. 182 (2009) 3855-3865
78. Mankowski J.L., et al. Cerebrospinal fluid markers that predict SIV CNS disease. J. Neuroimmunol. 157 (2004) 66-70
79. Marra C.M., et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids 23 (2009) 1359-1366
80. Masliah E., et al. Pathogenesis of HIV-1 associated neurodegeneration. Crit. Rev. Neurobiol. 10 (1996) 57-67
81. Masopust D. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location. J. Intern. Med. 265 (2009) 125-137
82. McArthur J.C., et al. Neurological complications of HIV infection. Lancet. Neurol. 4 (2005) 543-555
83. McGee B., et al. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin. Trials 7 (2006) 142-153
84. Melik-Parsadaniantz S., and Rostene W. Chemokines and neuromodulation. J. Neuroimmunol. 198 (2008) 62-68
85. Meucci O., et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14500-14505
86. Meucci O., et al. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8075-8080
87. Miller R.J., and Meucci O. AIDS and the brain: is there a chemokine connection?. Trends Neurosci. 22 (1999) 471-479
88. Monteiro de Almeida S., et al. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J. Neuroimmunol. 169 (2005) 144-152
89. Monteiro de Almeida S., et al. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. J. Neuroimmunol. 179 (2006) 180-185
90. Nottet H.S., and Gendelman H.E. Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol. Today 16 (1995) 441-448
91. Nottet H.S., et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J. Immunol. 156 (1996) 1284-1295
92. Nowacek A., and Gendelman H.E. NanoART, neuroAIDS and CNS drug delivery. Nanomed 4 (2009) 557-574
93. Ong E.L. Common AIDS-associated opportunistic infections. Clin. Med. 8 (2008) 539-543
94. Onofre G., et al. Scavenger receptor CD163 and its biological functions. Acta Medica (Hradec. Kralove) 52 (2009) 57-61
95. Peng F., et al. Mechanisms of platelet-derived growth factor-mediated neuroprotection-implications in HIV dementia. Eur. J. Neurosci. 28 (2008) 1255-1264
96. Perry S.W., et al. Adjunctive therapies for HIV-1 associated neurologic disease. Neurotox. Res. 8 (2005) 161-166
97. Persidsky Y., et al. A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J. Immunol. 158 (1997) 3499-3510
98. Persidsky Y., et al. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155 (1999) 1599-1611
99. Persidsky Y., et al. Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia. J. Leukoc. Biol. 68 (2000) 413-422
100. Persidsky Y., et al. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 1 (2006) 223-236
101. Petito C.K., et al. Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J. Neuropathol. Exp. Neurol. 45 (1986) 635-646
102. + and cytotoxic T lymphocytes are associated with, and may be specific for, human immunodeficiency virus type 1 encephalitis in patients with acquired immunodeficiency syndrome. J. Neurovirol. 12 (2006) 272-283
103. Poluektova L.Y., et al. Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J. Immunol. 168 (2002) 3941-3949
104. Potula R., et al. Association of platelet-derived growth factor-B chain with simian human immunodeficiency virus encephalitis. Am. J. Pathol. 165 (2004) 815-824
105. Pu H., et al. HIV-1 Tat protein-induced alterations of ZO-1 expression are mediated by redox-regulated ERK 1/2 activation. J. Cereb. Blood Flow Metab. 25 (2005) 1325-1335
106. Roberts E.S., et al. CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE). J. Neuropathol. Exp. Neurol. 63 (2004) 1255-1264
107. Rostene W., et al. Chemokines: a new class of neuromodulator?. Nat. Rev. Neurosci. 8 (2007) 895-903
108. + progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. J. Immunol. 161 (1998) 4169-4176
109. Schifitto G., et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66 (2006) 919-921
110. Schifitto G., et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J. Neurovirol. 15 (2009) 176-186
111. + T cells trafficking to cerebrospinal fluid in HIV-1 infection. J. Infect. Dis. 189 (2004) 2202-2212
112. Sharer L.R., et al. Multinucleated giant cells and HTLV-III in AIDS encephalopathy. Hum. Pathol. 16 (1985) 760
113. + hematopoietic stem cells contribute to turnover of brain perivascular macrophages in long-term repopulated primates. Am. J. Pathol. 174 (2009) 1808-1817
114. Toborek M., et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J. Neurochem. 84 (2003) 169-179
115. Tong N., et al. Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J. Immunol. 164 (2000) 1333-1339
116. Torheim E.A., et al. Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur. J. Immunol. 39 (2009) 1280-1287
117. Tsoupras A.B., et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?. AIDS Res. Hum. Retroviruses 24 (2008) 1079-1086
118. Varatharajan L., and Thomas S.A. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral. Res. 82 (2009) A99-109
119. Vergote D., et al. Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 19182-19187
120. Wang T., et al. Proteomic modeling for HIV-1 infected microglia-astrocyte crosstalk. PLoS ONE e2507 (2008) 3
121. Wang T., et al. HIV-1-infected astrocytes and the microglial proteome. J. Neuroimmune. Pharmacol. 3 (2008) 173-186
122. Westhorpe C.L., et al. Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. J. Leukoc. Biol. 85 (2009) 1027-1035
123. Yadav A., and Collman R.G. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. Neuroimmune. Pharmacol. (2009)
124. Yamamoto H., and Matano T. Anti-HIV adaptive immunity: determinants for viral persistence. Rev. Med. Virol. 18 (2008) 293-303
125. Yao H., et al. Involvement of TRPC channels in CCL2-mediated neuroprotection against tat toxicity. J. Neurosci. 29 (2009) 1657-1669
126. Zheng J., and Gendelman H.E. The HIV-1 associated dementia complex: a metabolic encephalopathy fueled by viral replication in mononuclear phagocytes. Curr. Opin. Neurol. 10 (1997) 319-325